DiaMedica Therapeutics Inc Overview
Industry: Biotechnology
Sector: Healthcare
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate Read MoreMavefund brings filings, fundamentals, valuation, price history and news for DiaMedica Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net loss was -$10M (from $7.7M). Cash was $51.3M.
Net loss
-$10M
from $7.7M
Cash
$51.3M
reported
What changed
- Net loss was -$10M (from $7.7M).
Guidance / outlook
The Company anticipates its current cash and short-term investments will be sufficient to fund its planned clinical studies and support corporate operations through 2027. ● Cash Flows – Net cash used in operating activities was $9.1 million for the three months ended March 31, 2026, compared to $7.1 million for the same period in the prior year.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
FORM 8-K
May 06, 2026
SEC filing
FORM 10-Q
May 06, 2026
SEC filing
FORM 8-K
Mar 31, 2026
Earnings release
EXHIBIT 99.1
Mar 31, 2026
SEC filing
FORM 10-K
Mar 30, 2026
SEC filing
FORM 8-K
Nov 12, 2025
Earnings release
EXHIBIT 99.1
Nov 12, 2025
SEC filing
FORM 10-Q
Nov 12, 2025
Earnings release
EXHIBIT 99.1
Aug 12, 2025
SEC filing
FORM 10-Q
Aug 12, 2025
SEC filing
FORM 8-K
Aug 12, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Headline from Yahoo Finance: DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Headline from Business Wire: DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Earnings Per Share
Score 3.00/5
DiaMedica Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.24/5
DiaMedica Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.21/5
DiaMedica Therapeutics Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.02/5
DiaMedica Therapeutics Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios